Comparison of cost-effectiveness of oral rapamycin plus bare-metal stents versus first generation of drug-eluting stents (from the randomized oral rapamycin in Argentina [ORAR] 3 Trial)


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
22109997

DOI
10.1002/ccd.23352

Indexing Status
Subject indexing assigned by NLM

MeSH
Administration, Oral; Aged; Argentina; Cardiovascular Agents /administration & dosage /economics; Chi-Square Distribution; Combined Modality Therapy; Coronary Artery Disease /drug therapy /economics /therapy; Coronary Restenosis /economics /etiology; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug-Eluting Stents /economics; Female; Health Care Costs; Hospital Costs; Humans; Kaplan-Meier Estimate; Male; Metals /economics; Middle Aged; Multivariate Analysis; Myocardial Infarction /economics /etiology; Percutaneous Coronary Intervention /adverse effects /economics /instrumentation /mortality; Proportional Hazards Models; Prosthesis Design; Risk Assessment; Risk Factors; Sirolimus /administration & dosage /economics; Stents /economics; Stroke /economics /etiology; Time Factors; Treatment Outcome

AccessionNumber
22014010398

Date bibliographic record published
14/03/2014